Tectonic therapeutic announces first quarter 2025 financial results and recent business highlights

Watertown, mass., may 08, 2025 (globe newswire) -- tectonic therapeutic, inc. (nasdaq: tecx) (“tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of g-protein coupled receptors (gpcrs), today announced financial results for the first quarter ended march 31, 2025, and provided an overview of recent business highlights.
TECX Ratings Summary
TECX Quant Ranking